Miglietta F, Ragazzi M, Fernandes B, Griguolo G, et al. A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer. Clin Cancer Res 2023 Jul 7:CCR-23-0480. doi: 10.1158/1078-0432.CCR-23-0480.
PMID: 37417941